Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
8.55 (1y: -9%)
Market Cap 133.4 M P/E(ttm) 43.30
Enterprise Value 117.16 M P/B 4.90
GENT- NAS (USA)
Gentium SpA
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$8.55
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt 8.086
GENT's Cash to Debt is ranked lower than
233645% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. GENT: 8.086 )
GENT' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 8.09
Equity to Asset 0.704
GENT's Equity to Asset is ranked lower than
258398% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. GENT: 0.704 )
GENT' s 10-Year Equity to Asset Range
Min: -0.27   Max: 0.7
Current: 0.7
-0.27
0.7
F-Score: 8
Z-Score: 3.95
M-Score: -2.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 2.50
GENT's Operating margin (%) is ranked lower than
303951% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.90 vs. GENT: 2.50 )
GENT' s 10-Year Operating margin (%) Range
Min: -433.2   Max: 18.2
Current: 2.5
-433.2
18.2
Net-margin (%) 2.7
GENT's Net-margin (%) is ranked lower than
304878% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. GENT: 2.7 )
GENT' s 10-Year Net-margin (%) Range
Min: -468   Max: 16.6
Current: 2.7
-468
16.6
ROE (%) 3.8
GENT's ROE (%) is ranked lower than
308642% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.40 vs. GENT: 3.8 )
GENT' s 10-Year ROE (%) Range
Min: -190.5   Max: 555.3
Current: 3.8
-190.5
555.3
ROA (%) 2.7
GENT's ROA (%) is ranked lower than
305810% of the 327 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. GENT: 2.7 )
GENT' s 10-Year ROA (%) Range
Min: -74   Max: 16.5
Current: 2.7
-74
16.5
ROC (Joel Greenblatt) (%) 11.70
GENT's ROC (Joel Greenblatt) (%) is ranked lower than
315457% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.80 vs. GENT: 11.70 )
GENT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3494   Max: 93.6
Current: 11.7
-3494
93.6
Revenue Growth (%) 28.6
GENT's Revenue Growth (%) is ranked lower than
434782% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.10 vs. GENT: 28.6 )
GENT' s 10-Year Revenue Growth (%) Range
Min: -30.1   Max: 33
Current: 28.6
-30.1
33
» GENT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q4 2011

GENT Guru Trades in Q4 2011

Jim Simons 96,900 sh (+5.56%)
» More
Q1 2012

GENT Guru Trades in Q1 2012

Jim Simons 77,200 sh (-20.33%)
» More
Q2 2012

GENT Guru Trades in Q2 2012

Jim Simons 72,300 sh (-6.35%)
» More
Q3 2012

GENT Guru Trades in Q3 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GENT



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/E(ttm) 43.30
GENT's P/E(ttm) is ranked lower than
297619% of the 336 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.80 vs. GENT: 43.30 )
GENT' s 10-Year P/E(ttm) Range
Min: 14.63   Max: 3755.7
Current: 43.3
14.63
3755.7
P/B 4.90
GENT's P/B is ranked lower than
238095% of the 420 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.51 vs. GENT: 4.90 )
GENT' s 10-Year P/B Range
Min: 0.38   Max: 10.19
Current: 4.9
0.38
10.19
P/S 3.30
GENT's P/S is ranked lower than
231481% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. GENT: 3.30 )
GENT' s 10-Year P/S Range
Min: 0.52   Max: 50.52
Current: 3.3
0.52
50.52
PFCF 40.70
GENT's PFCF is ranked lower than
411522% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.36 vs. GENT: 40.70 )
GENT' s 10-Year PFCF Range
Min: 2.63   Max: 171.67
Current: 40.7
2.63
171.67
EV-to-EBIT 43.5
GENT's EV-to-EBIT is ranked lower than
273224% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. GENT: 43.5 )
GENT' s 10-Year EV-to-EBIT Range
Min: 12.4   Max: 210.8
Current: 43.5
12.4
210.8

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 53.1
GENT's Price/Net Cash is ranked lower than
751879% of the 133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. GENT: 53.1 )
GENT' s 10-Year Price/Net Cash Range
Min: 24.2   Max: 75.7
Current: 53.1
24.2
75.7
Price/Net Current Asset Value 20.2
GENT's Price/Net Current Asset Value is ranked lower than
255754% of the 391 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. GENT: 20.2 )
GENT' s 10-Year Price/Net Current Asset Value Range
Min: 9.8   Max: 48.5
Current: 20.2
9.8
48.5
Price/Tangible Book 4.9
GENT's Price/Tangible Book is ranked lower than
257732% of the 388 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. GENT: 4.9 )
GENT' s 10-Year Price/Tangible Book Range
Min: 0.7   Max: 8.1
Current: 4.9
0.7
8.1
Price/Median PS Value 0.7
GENT's Price/Median PS Value is ranked lower than
243902% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. GENT: 0.7 )
GENT' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 8.4
Current: 0.7
0.2
8.4
Price/Graham Number 6.2
GENT's Price/Graham Number is ranked lower than
324675% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. GENT: 6.2 )
GENT' s 10-Year Price/Graham Number Range
Min: 2.5   Max: 8.3
Current: 6.2
2.5
8.3
Earnings Yield (Greenblatt) 2.30
GENT's Earnings Yield (Greenblatt) is ranked lower than
277008% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. GENT: 2.30 )
GENT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 8.1
Current: 2.3
0.5
8.1
Forward Rate of Return (Yacktman) -2.5
GENT's Forward Rate of Return (Yacktman) is ranked lower than
704225% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.10 vs. GENT: -2.5 )
GENT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -45.3   Max: -2.6
Current: -2.5
-45.3
-2.6

Business Description

Gentium SpA was originally formed in 1993 as Pharma Research S.r.L., an Italian private limited Company. In December 2000, it changed from a private limited company to an Italian Corporation. In July 2001, the Company changed its name to Gentium S.p.A. In June 2005, it consummated an initial public offering of its ADSs, which began trading on the American Stock Exchange. It is a biopharmaceutical Company focused on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on single-stranded DNA extracted from pig intestines. Its development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease, or VOD, a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments, that are given prior to stem cell transplantation. Severe VOD is the most extreme form of VOD and is associated with multiple-organ failure and high rates of morbidity and mortality. The Company has completed two clinical trials, a Phase III trial of defibrotide for the treatment of severe VOD in the U.S., Canada and Israel and a Phase II/III pediatric trial in Europe for the prevention of VOD. It is currently completing certain preclinical and clinical studies requested by regulatory authorities. It also manufactures defibrotide and sulglicotide at its manufacturing facility near Como, Italy, and it leases a facility from one of its affiliates, Sirton, to manufacture urokinase. These products are active pharmaceutical ingredients used to make other drugs. Its strategic objective is to obtain regulatory approval for defibrotide to treat and prevent VOD. Other products includes: Sulglicotide and Urokinase. The Company faces competition in both the development and marketing of its product candidates.
Company Website
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial